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Abstract 
Background: Non-adherence to tuberculosis (TB) treatment can result in an emergence of new strains, prolonged 
infectiousness, drug resistance and poor treatment outcomes. Thus, assessment of the level of adherence to anti-TB 
treatment, treatment outcomes and identifying factors associated with non-adherence and poor treatment outcomes 
are vital for improving TB treatment adherence and treatment outcomes in the study area. The main objectives of the 
current study were to assess the level of adherence to anti-TB treatment among patients taking anti-TB drug treat-
ment and to identify factors associated with non-adherence. Whereas, the secondary objectives were to assess treat-
ment outcomes and factors associated with poor treatment outcomes among TB patients previously treated at the 
health institutions of Alamata District, northeast Ethiopia.
Methods: In a health facility-based cross-sectional study, TB patients who were taking anti-TB drug treatment were 
interviewed using a structured questionnaire to evaluate level of adherence to anti-TB treatment. TB treatment out-
comes were evaluated using data generated from a record review of previous TB patients who were treated at health 
facilities of Alamata District from January 2007 to June 2012. Adherence data and treatment outcomes data were 
computerized separately using Epi-Data version 3.1 and analyzed using STATA version 10.0.
Results: Between November 2012 and January 2013, 116 (58.0 %) male TB patients and 84 (42.0 %) female TB 
patients were interviewed, of whom 77.5 % were new cases, 23.5 % were smear-positive pulmonary TB (SPPTB) cases, 
26.5 % were smear-negative PTB (SNPTB) cases and 50.0 % were extra pulmonary (EPTB) cases. The overall adherence 
rate to anti-TB treatment was 88.5 %. The main reasons for the non-adherent patients were forgetting to take medica-
tion, being away from home, drug side effects, being unable to go to the health facilities on the date of appointment 
and being hospitalized. In the TB treatment outcomes component of the current study, records of 4,275 TB patients 
were reviewed and the overall treatment success rate was 90.1 %. Two-hundred fifteen (5.0 %) patients had unsuc-
cessful treatment outcomes, of whom 76 (35.3 %) defaulted, 126 (58.6 %) died and 13 (6.1 %) had treatment failure. 
Significant predictors of unsuccessful treatment outcomes were being positive for human immunodeficiency virus 
(HIV) infection [adjusted odds ratio (aOR) = 2.1, 95 % CI 1.5–3.0], being SPPTB case (aOR = 3.4, 95 % CI 2.4–4.8), being 
SNPTB case (aOR = 2.0, 95 % CI 1.5–2.8)], and being re-treatment cases (aOR = 2.6, 95 % CI 1.5–3.7).
Conclusion: In the present study area, there was a high level of adherence to anti-TB treatment and also a high TB 
treatment success rate. However, still further effort like health education to patient or family is needed to reduce 
those factors which affect adherence and treatment success rates in order to ensure higher rates of adherence and 
treatment success than the currently observed in the present study area.
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Background
Tuberculosis (TB) continues to be a major health con-
cern worldwide [1]. In particular, the emergence of drug 
resistant strains of TB is considered a global threat to 
the control of TB. Nevertheless, TB is a curable disease 
if treatment is received quickly and appropriately. Thus, 
rapid and accurate diagnosis and the use of effective 
anti-TB treatments are priority tools not only for mini-
mizing morbidity and mortality, but also for mitigating 
the spread of TB among the population. However, TB 
patients who are not cured or non- adherent to their 
treatment not only pose a serious risk both for individu-
als and community [2], but also present a challenge to 
effective TB control [3].
Non-adherence to anti-TB treatment may result in the 
emergence of multidrug resistant TB (MDR-TB), pro-
longed infectiousness and poor TB treatment outcomes 
[4, 5]. In previous studies, patients related factors includ-
ing feeling better, forgetfulness, lack of knowledge on the 
benefits of completing a treatment course, running out of 
drugs at home, distance to the health facility, HIV sero-
positivity, alcohol abuse, use of herbal medication, stigma 
and male gender were significantly associated with non-
adherence to an anti-TB treatment [6–12]. Non-adher-
ence to an anti-TB drug treatment was also significantly 
associated with drug side effects, being in the continu-
ation phases of chemotherapy, pill burden, lack of ade-
quate communication with health professionals and lack 
of family support [9, 10, 12]. A studys done in the south-
ern part of Ethiopia found that re-treatment cases, hav-
ing a positive smear at the second month of follow-up, 
smear-negative pulmonary TB, being older than 55 years 
and being male were significantly associated with unsuc-
cessful TB treatment outcomes [13]. In a study conducted 
among smear positive TB patients in northern Ethiopia 
[14],, being older than 40 years of age, having family size 
of more than 5 persons, being unemployed and being re-
treatment cases were significantly associated with unsuc-
cessful treatment outcomes.
Taken together, the above-mentioned studies indi-
cate that different factors have been associated with 
non-adherence to anti-TB treatment and TB treatment 
outcomes in different countries as well as in different 
communities in the same country. Hence, information 
on the level of adherence to TB treatment, treatment 
outcomes and identifying specific factors which affect 
adherence to TB treatment and treatment outcomes 
in different settings are important to understand spe-
cific problems and accordingly design community/
population-based appropriate strategies to reduce these 
problems.
Ethiopia is among the 22 highest TB burden countries 
(HBCs) in the world [1]. According to hospital statistics 
data, TB is the leading cause of morbidity, the third cause 
of hospital admission and the second cause of death in 
Ethiopia [15]. In Ethiopia, a control strategy for TB was 
initiated in the early 1960s with the establishment of TB 
centres and sanatoriums in a few places, which then fol-
lowed by the direct observation treatment short course 
(DOTS) program in the early 1990s [15]. Currently, the 
DOTS health facility coverage is 95  % and the major-
ity (95  %) of the existing health centers/facilities are 
implementing DOTS-based TB treatment services. In 
the Tigray Regional State of Ethiopia, DOTS was intro-
duced in 1995 and the program has now been intro-
duced in all hospitals, all health centers and in most of 
the health posts. Nevertheless, there is little information 
on patients’ adherence to anti-TB treatment as well as TB 
treatment outcomes in this Regional State [14]. There-
fore, the two components of the current study were (1) 
to determine the level of anti-TB treatment adherence 
and to understand factors associated with non- adher-
ence among TB patients who were on treatment dur-
ing the data collection period, and (2) to retrospectively 
review records of TB patients and evaluate anti-TB treat-
ment outcomes as well as identify factors associated with 
poor treatment outcomes in Alamata District of Tigray 
Regional State of Ethiopia.
Methods
Study area and population
The current study was conducted in Alamata District 
of Tigray Region State, located at a distance of 600  km 
northeast of Addis Ababa. Based on the 2007 national 
census conducted by the Central Statistical Agency of 
Ethiopia (CSA), this District has a total population of 
85,403 (42,483 males and 42,920 females) [16]. During 
the current data collection, the District had one hospi-
tal, 6 health centers and 15 health posts, and all of these 
institutions were providing the DOTS service. Data for 
the current study was obtained from the attendees or 
patient records of the hospital and five health centers, 
namely, Alamata Hospital, Alamata Health Center, Gar-
jale Health Center, Selen Wuha Health Center, Timuga 
Health Center and Waja Health Center.
Study design and sample size
A health facility-based cross-sectional study design was 
used to recruit study participants to assess the level of 
adherence to anti-TB treatment among TB patients who 
were receiving their treatment at the health facilities of 
Alamata District between November 2012 and January 
2013. A sample size of 200 was determined to estimate 
level of adherence to anti-TB treatment assuming 85  % 
level of adherence [11, 12] with a 5 % margin of error and 
95 % confidence. A retrospective cohort study design was 
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employed to assess TB treatment outcomes for the last 
five and half years (between January 2007 and June 2012).
Study participants and data collection for the assessment 
of treatment adherence
All TB patients age over 15 years, who were on anti-TB 
treatment for at least 1  month during the study period 
and who were mentally stable, able to communicate, 
and provide informed consent were eligible for inclu-
sion in the assessment of treatment adherence. A struc-
tured questionnaire was used to interview participants 
to evaluate level of adherence to anti-TB treatment [17]. 
The questionnaire recorded demographic and socio-eco-
nomic characteristics of the study participants, general 
information about TB, information on treatment adher-
ence and problems associated with non-adherence. The 
questionnaire was prepared in English and translated 
into the local language (Tigrigna). Trained data collec-
tors at the respective health facilities interviewed the 
participants in their local language. The questionnaire 
was pre-tested and cheeked for clarity and consistency. 
During the data collection, the completed question-
naires were reviewed and checked for completeness, 
accuracy and consistency. Patients’ knowledge about TB 
was ascertained based on their responses to 11 questions 
posed during a face-to-face interview. To generate vari-
ables to be used to evaluate the level of overall knowledge 
of respondents, all responses to the 11 questions were 
coded (i.e. correct answer was coded as 1 and incorrect 
answer was coded as 0) and added mathematically. Those 
respondents who scored equal to and/or above the mean 
were considered to have a high level of overall knowl-
edge (or to be knowledgeable) of TB, while those scor-
ing below the mean were considered to have low levels 
of overall knowledge (or be Non- knowledgeable) of TB.
Data collection for the assessment of TB treatment 
outcomes
Treatment outcomes were investigated by reviewing the 
records of all TB patients who were diagnosed with active 
TB as defined by WHO criteria and who had received 
anti-TB treatment between January 2007 and June 2012 
using a data collection sheet. The data collection sheet 
contained socio-demographic characteristics of the study 
participants and information on treatment outcomes 
(cured, treatment completed, defaulted, died or treat-
ment failed).
Description of outcome variables
The outcome variables are (1) adherence to anti-TB treat-
ment as reported by patients attending health facilities 
for their regular anti-TB medication during a face-to-face 
interview, and (2) TB treatment outcomes as determined 
through a review of patents’ records for the past 5 years 
and 6  months. The overall adherence to anti-TB treat-
ment was determined based on the self-report of the 
study participants (i.e. the study participants were asked 
to report the total number of days they missed the pre-
scribed medication/anti-TB tablets) for the last 30 days. 
The adherence percentage was calculated as the number 
of doses taken by the respondent as prescribed by the 
clinician, divided by the number of doses prescribed to 
the respondent in the last 30  days and then multiplied 
by 100. Those study participants who took at least 95 % 
of the medication as prescribed by the clinician were 
considered to be adherent to anti-TB treatment in the 
last 30 days, while those who took less than 95 % of the 
medication were considered as non-adherent to anti-TB 
treatment in the last 30 days. Moreover, non-adherence 
was evaluated as the doses of medication missed in the 
previous day, in the past 3  days and in the past 7  days. 
Treatment outcomes were assessed using a retrospec-
tive record review of patients, based on the WHO and 
national guidelines definition for TB treatment outcomes 
and monitoring [18]. For the purpose of modeling, treat-
ment outcomes were dichotomized in such a way that 
cured and treatment completed patients were placed in 
one category and all other possibilities were clustered in 
another category.
Data processing and analysis
Data collected from participants of the anti-TB adher-
ence study and data collected from the retrospective 
record review of previously treated TB patients were 
double-entered into two different files using EpiData 
software, version 3.1 (Odense, Denmark: The Epidata 
Association, 2003). The two data sets were analyzed inde-
pendently using STATA version 10.0 (StataCorp, College 
Station, TX, USA: Stata Corporation 2007). The effects 
of predefined potential risk factors on the likelihood of 
adherence were modeled using logistic regression, and 
odds ratios with corresponding 95 % confidence intervals 
were reported as the measures of the degree of associa-
tions. Variables significantly associated with the likeli-
hood of treatment adherence in the bivariate analysis (i.e. 
P value  <0.05) were included in a multivariable logistic 
regression model to determine their adjusted relative 
contributions in predicting the likelihood of treatment 
adherence. Using the retrospectively extracted treatment 
outcomes and other patient factors, similar procedures 
were followed to identify variables which were signifi-
cantly associated with the likelihood of having unsuccess-
ful treatment outcomes while simultaneously adjusting 
for the effect other variables. Results were reported as 
being statistically significant whenever p value was less 
than 5 %.
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Ethical approval
Ethical approval was obtained from the Institutional 
Review Board (IRB) of Aklilu Lemma Institute of 
Pathobiology, Addis Ababa University. Permission 
was obtained from Tigray Regional Health Bureau and 
Alamta District Health Office before starting the study. 
Since the majority (68 %) of the study participants were 
illiterate, verbal consent was obtained before interview-
ing each participant, and parental consent was obtained 
for participants under 18 years of age.
Results
Background characteristics of participants who 
participated in the anti‑TB treatment adherence study
Background characteristics of the participants who par-
ticipated in anti-TB treatment adherence study and the 
associations of these characteristics with the likelihood 
of adherence to anti-TB treatment are summarized in 
Table 1. A total of 200 patients (58 % males, age ranged 
15–78 years, mean age, 34.8 years) were interviewed. The 
majority (77.5 %) of the participants were new TB cases, 
while 47.0  % were in the intensive phase of treatment. 
About 89.0  % of the patients knew their HIV status, of 
whom 14.6 % were HIVsero-positive. With respect to col-
lecting anti-TB medication from health center/hospital, 
130 (65.0  %) respondents said that they get their medi-
cation daily, 17 (8.5 %) mentioned that they collect their 
tablets weekly and 53 (26.5 %) said that they collect their 
tablets monthly.
The average delay time before being served at the 
health institution was 10.2  min (SD  =  11.3) and 187 
(93.5  %) respondents reported that they were satisfied 
by the services of the health institution. Seventy-four 
patients (37.0 %) said that they were counseled on each 
visit, 74 patients were never counseled, 98.5  % of the 
study participants had open communication with the 
health providers, and 99 % of the study participants said 
that the care providers provided privacy for them during 
visiting the health facility.
Forty-eight participants (24.0  %) had no informa-
tion on the causative agent of TB and 38 participants 
(19 %) attributed the cause of TB to a bacteria/germ. The 
remaining respondents suggested dust (20.0 %), stress or 
work load (16.5  %), chill (13.5  %) and smoking (7  %) as 
causative agents of TB. The majority (87.5 %) of the study 
participants knew that TB is a transmittable disease and 
50.0 % were able to mention at least two symptoms, with 
cough being the most identified symptom (54.5 %). When 
participants were asked about the consequence of inter-
rupting or stopping taking anti-TB drugs, 73(36.5  %) 
mentioned death. When the study participants were 
asked about the curability of the disease, 99  % of the 
respondents reported that TB is a curable disease. But 
when they were asked about the duration of TB treat-
ment, only 84.5  % reported the correct duration of TB 
treatment. Based on their response to the questions, 73 
(36.5 %) of the respondents were categorized as having a 
high level of knowledge about TB.
Level of adherence to anti‑TB treatment
The level of adherence to anti-TB treatment was 96  % 
with the last 3  days, 98.5  % within the last 7  days and 
88.5  % within the last 30  days. Non-adherence within 
the last 30  days was 44.4  % among smokers, 40.0  % 
among khat chewers, 26.9  % among those HIV sero-
positive and 22.2  % among frequent alcohol consum-
ers (Table  1). Relatively, re-treatment cases were less 
adherent to anti-TB treatment (17.2  %) compared to 
new cases (10.3  %). The highest proportion of non-
adherence within the last 30 days was observed among 
patients who received their treatment at Selen Wuha 
Health Center when compared to patients who attended 
their treatment at the rests of health centers (Fig.  1). 
The reasons reported for non-adherence were forget-
ting to take their medication (n = 8; 34.8 %), spending 
time away from home (n =  6; 26.1  %), failure to go to 
health facilities on the exact day of appointment (n = 3; 
13.0 %), drug side effects (n = 1, 4.4 %), being admitted 
to a hospital (n = 4; 17.4 %) and other personal reasons 
(n = 1; 4.4 %).
Factors associated with non‑adherence to anti‑TB 
treatment
Results from logistic regression analysis, which was car-
ried out to assess the associations of selected socio-
demographic and other risk factors and the likelihood of 
non-adherence to anti-TB treatment are summarized in 
Tables 1 and 2. In a univariable logistic regression analy-
sis, being younger than 24  years of age, HIV sero-posi-
tivity, frequent alcohol consumption, having a smoking 
habit, having a khat chewing habit, a lack of satisfaction 
with health services and prolonged waiting time at the 
health facility to get medical services were significantly 
associated with non-adherence to anti-TB treatment. In 
a multivariable logistic regression model, being younger 
than 24 years and prolonged waiting time at health facili-
ties before getting medical attention maintained marginal 
statistical significance.
Background characteristics of study participants included 
in TB treatment outcomes
Between January 2007 and June 2012, a total of 4275 
patients (59  % males), with a mean age of 31.7  years, 
were registered to initiate anti-TB treatment at the study 
health facilities. The background characteristics are sum-
marized in Table 3. The majority (97.4 %) were new cases, 
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while 589 (13.8 %), 1249 (29.2 %) and 2437 (57.0 %) were 
registered as SPPTB, SNPTB and EPTB cases, respec-
tively. Among 2864 patients (67 %) who were tested for 
HIV, 587 (20.5  %) were sero-positive and HIV infection 
was significantly higher among urban than rural TB 
patients (17.8 versus 10.2 %, P < 0.001).
Outcomes of anti‑TB treatment
The majority (90.1  %) had successful treatment out-
comes, while 215 (5.0 %) had unsuccessful treatment out-
comes [i.e. 35.3  % (76/215) defaulted, 58.6  % (126/215) 
died and 6.1 % (13/215) had treatment failure]. The over-
all rate of default was 1.8 %, with 61.8 % of the defaulting 
Table 1 Association of background characteristics of study participants (n = 200) and level of adherence to anti-TB treat-
ment
PTB pulmonary TB, EXPTB extra pulmonary TB




Adherence status Crude OR  
(95 % CL)
P value




Sex Male 116 (58.0) 15 (12.9) 101 (87.1) 1.41 (0.6, 3.5) 0.46
Female 84 (42.0) 8 (9.5) 76 (90.5) Reference
Age (year) 15–24 58 (29.0) 10 (17.2) 48 (82.8) 5.1 (1.3, 24.5) 0.04
25–34 54 (27.0) 8 (14.8) 46 (85.2) 4.3 (0.9,21.1) 0.08
35–44 37 (18.5) 3 (8.1) 34 (91.9) 2.2 (0.3, 13.6) 0.41
45+ 51 (25.5) 2 (3.9) 49 (96.1) Reference
Marital status Unmarried 63 (31.5) 11 (17.5) 52 (82.5) 2.3 (0.6, 8.7) 0.24
Married 102 (51.0) 9 (8.8) 93 (91.2) 1.0 (0.3, 4.1) 0.96
Other 35 (17.5) 3 (8.6) 32 (91.4) Reference
Treatment history New cases 155 (77.5) 7 (10.3) 148 (89.7) Reference
Re-treatment cases 35 (17.5) 6 (17.2) 29 (82.9) 1.8 (0.7, 5.0) 0.26
Education Illiterate 121 (60.5) 9 (7.4) 112 (92.6) Reference
Read and write 20 (10.0) 3 (15.0) 17 (85.0) 2.2 (0.5, 8.9) 0.27
Primary (1–8) 33 (16.5) 7 (21.2) 26 (78.8) 3.4 (1.1, 9.8) 0.03
Secondary and above 26 (13.0) 4 (15.4) 22 (84.6) 2.3 (0.6, 8.0) 0.21
Distance home-clinic 
(km)
0–5 km 92 (46.0) 9 (9. 8) 83 (90.2) Reference
>5 km 108 (54.0) 14 (6.5) 94 (93.5) 1.4 (0.6, 3.3) 0.48
Residence area: Urban 51 (25.5) 8 (15.7) 43 (84.3) 1.7 (0.7, 4.2) 0.28
Rural 149 (74.5) 15 (10.1) 134 (89.9) Reference
Family size 1–5 138 (69.0) 15 (10.9) 123 (89.1) Reference
>5 62 (31.0) 8 (12.9) 54 (87.1) 1.2 (0.5, 3.0) 0.67
Form of TB PTB 100 (50.0) 14 (14.0) 86 (86.0) 1.7 (0.8,4.0) 0.27
EPTB 100 (50.0) 9 (9.0) 91 (91.0) Reference
Means of transporta-
tion
Foot 118 (59.0) 18 (15.2) 100 (84.8) 2.8 (1.0,7.8) 0.05
Vehicle 82 (41.0) 5 (6.1) 77 (93.9) Reference
HIV status Positive 26 (13.0) 7 (26.9) 19 (73.1) 3.4 (1.2, 9.3) 0.02
Negative 152 (76.9)) 15 (9.9) 137 (90.1) Reference
Unknown 22 (11.0) 1 (4.5) 21 (95.5) 0.4 (0.1, 3.5) 0.43
Alcohol use Yes 36 (18.0) 8 (22.2) 28 (77.8) 2.8 (1.1, 7.3) 0.03
No 164 (82.0) 15 (9.2) 149 (90.8) Reference
Family income <501 birr 111 (55.5) 10 (9.0) 101 (91.0) Reference
≥501 birr 89 (44.5) 13 (14.6) 76 (85.4) 1.7 (.8, 4.2) 0.22
Chewing khat Yes 10 (5.0) 4 (40.0) 6 (60.0) 6.0 (1.6, 23.2) 0.01
No 190 (95.0) 19 (10.0) 171 (90.0) Reference
Smoking Yes 9 (4.5) 4 (44.4) 5 (55.6) 7.2 (1.8,29.3) 0.01
No 191 (95.5) 19 (9.9) 172 (90.1) Reference
Knowledge of TB Knowledgeable 73 (36.5) 8 (11.0) 65 (89.0) Reference
Non-knowledgeable 167 (63.5) 15 (11.8) 112 (88.2) 1.1 (0.4, 2.7) 0.86
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cases occurring among rural residents. Unsuccessful 
treatment outcomes were more frequent among patients 
who received re-treatment regimens than among new 
cases (18.2 versus 4.7 %, P < 0.001). Treatment outcomes 
also varied with disease classification; 10  % of patients 
with SPPTB had unsuccessful treatment outcomes as 
compared to 6.4  % of patients with SNPTB and 3.2  % 
of patients with EPTB (p < 0.001). Cure rate was 84.7 % 
among new cases and 69.8 % among re-treatment cases. 
The proportion of death was 5.1 % in SPPTB cases, 4.2 % 
in SNPTB cases, and 1.8  % in EPTB cases. A high pro-
portion of the treatment failure cases was observed in the 
year 2011, which accounted for 53.8  % (Table  3). Treat-
ment success varied from 86.1 to 95.9 % across the health 
facilities, with a 95.9 % treatment success obtained at the 
Alamata Health Center and 86.1 % at the Timuga Health 
Center (Fig. 2).
In the multivariable logistic regression model, there 
was significant heterogeneity in the odds of having 
unsuccessful treatment outcomes across years of initi-
ating treatment and across health facilities in the study 
area (Table 4). Moreover, the odds of having unsuccessful 
treatment outcomes was significantly increased among 
SPPTB and SNPTB patients compared to EPTB cases, 
among HIV sero-positive patients compared to HIV 
sero-negative, and among retreatment cases compared to 
new cases (Table 4).
Discussion
Non-adherence to anti-TB treatment might lead to an 
increased risk of drug resistance and a prolonged infec-
tiousness, in addition to relapse and death [19]. Thus, 
data obtained from this adherence survey is essential 
for planning, implementing and evaluating advocacy, 
communication and social mobilization (ACSM) work. 
Between November 2012 and January 2013, 200  TB 
patients who were on anti-TB drug treatment were inter-
viewed using a structured questionnaire to evaluate level 
of adherence to anti-TB treatment in Alamata District, 
90.5 88.3 86.4 83.3 89.5 
100 



















Fig. 1 Adherence (expressed in percent) across health facilities in 
Alamata District. Adherence was measured by self-report and it is 
based on the ratio of the number of doses taken as per instruction 
divided by the number of dose prescribed over the last 30 days
Table 2 Association of service provider and health facility related factors with adherence to TB treatment (n = 200)
Characteristics Response categories Treatment adherence status Crude OR  
(95 % CL)
P value
No. non‑adhered (%) No. adhered (%)
Patient satisfaction by health service Yes 18 (9.6) 169 (90.4) Reference
No 5 (38.5) 8 (61.5) 5.9 (1.7, 19.8) 0.004
Health education provided during treatment Yes 18 (10.3) 157 (89.7) Reference.
No 5 (20.0) 20 (80.0) 2.2 (0.7, 6.5) 0.16
Taking monthly appointment card Yes 18 (9.8) 165 (90.2) Reference
No 5 (29.4) 12 (70.6) 3.8 (1.2, 12.0) 0.02
Counseling about TB treatment First visit 8 (9.5) 76 (90.5) 1.2 (0.4, 3.6) 0.76
On each visit 6 (8.1) 68 (91.9) Reference
Once a while 2 (11.1) 16 (88.9) 1.4 (0.3, 7.7) 0.67
Never counseled 7 (29.2) 17 (70.8) 4.7 (1.4, 15.7) 0.01
Delay time before served 1–10 min 12 (7.8) 141 (92.2) Reference
11+ min 11 (23.7) 36 (76.6) 3.6 (1.5, 8.8) 0.01
Open communication with health providers Yes 22 (11.2) 175 (88.8) Reference
No 1 (33.3) 2 (66.7) 0.3 (0.1, 2.9) 0.27
Frequency of dose he/she takes Daily 19 (14.6) 111 (85.4) 4.4 (0.1, 19.5) 0.05
Weekly 2 (11.8) 15 (88.2) 3.4 (0.4, 26.2) 0.24
Monthly 2 (3.8) 51 (96.2) Reference
Privacy by health providers Yes 22 (11.1) 176 (88.9) 8.0 (0.5, 132.5) 0.15
No 1 (50) 1 (50) Reference
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northeast Ethiopia. The results showed that an overall 
treatment adherence of 1  month was 88.5  %, which is 
higher than the level of adherence reported previously 
from Southwest Ethiopia [20]. The difference in adher-
ence rates might be explained by the difference in the 
characteristics of study participants, as their study par-
ticipants were only HIV positive patients, while the cur-
rent study participants were a combination of those HIV 
seropositive and HIV seronegative. In contrast to the 
current study, a previous Ethiopian study [11] reported a 
significant difference in adherence to anti-TB treatment 
during the intensive and continuation phases of TB treat-
ment. The present study demonstrated a similar level of 
non-adherence (11.5  %) to the results of studies from 
Table 3 Anti-TB treatment outcomes for five consecutive years stratified by selected background characteristics (n = 4275)






Sex Male 312 (12.4) 1951 (77.4) 70 (2.7) 8 (0.3) 49 (2.0) 132 (5.2)
Female 179 (10.2) 1411 (80.5) 56 (3.2) 5 (0.3) 27 (1.5) 75 (4.3)
Age 0–14 20 (3.5) 495 (87.6) 13 (2.3) 0 (0.0) 10 (1.8) 27 (4.8)
15–24 164 (16.0) 776 (75.8) 15 (1.5) 5 (0.5) 19 (1.8) 45 (4.4)
25–34 137 (13.5) 764 (75.4) 34 (3.4) 4 (0.4) 18 (1.8) 56 (5.5)
35–44 83 (12.0) 540 (77.5) 26 (3.7) 3 (0.4) 15 (2.1) 30 (4.3)
45+ 87 (8.9) 787 (80.6) 38 (4.0) 1 (0.1) 14 (1.4) 49 (5.0)
Residence Urban 251 (12.2) 1628 (79.3) 64 (3.2) 9 (0.4) 29 (1.4) 72 (3.5)
Rural 240 (10.8) 1734 (78.0) 62 (2.8) 4 (0.2) 47 (2.1) 135 (6.1)
Form of TB Smear positive PTB 491 (83.4) 0 (0.0) 30 (5.1) 13 (2.2) 16 (2.7) 39 (6.6)
Smear negative PTB – 1118 (89.5) 52 (4.2) – 27 (2.2) 52 (4.2)
EPTB – 2244 (92.0) 44 (1.8) – 33 (1.4) 116 (4.8)
Treatment history New cases 454 (10.9) 3313 (79.5) 117 (2.8) 7 (0.2) 71 (1.7) 203 (4.9)
Retreatment cases 37 (33.6) 49 (44.5) 9 (8.3) 6 (5.5) 5 (4.5) 4 (3.6)
HIV status Positive 90 (15.3) 406 (69.2) 39 (6.6) 3 (0.5) 10 (1.7) 39 (6.7)
Negative 244 (10.7) 1813 (79.8) 45 (2.0) 6 (0.3) 50 (2.2) 114 (5.0)
Unknown 157 (11.0) 1143 (80.7) 42 (3.0) 4 (0.3) 16 (1.2) 54 (3.8)
Year of enrollment 2007 81 (12.6) 514 (80.0) 21 (3.3) 2 (0.3) 5 (0.8) 19 (3.0)
2008 81 (9.6) 673 (80.1) 33 (4.0) 1 (0.1) 10 (1.2) 42 (5.0)
2009 87 (9.8) 713 (79.9) 20 (2.2) 1 (0.1) 15 (1.7) 56 (6.3)
2010 107 (13.4) 603 (75.6) 19 (2.4) 1 (0.1) 14 (1.7) 54 (6.8)
2011 102 (12.9) 614 (77.7) 23 (2.9) 7 (0.9) 17 (2.2) 27 (3.4)
2012 33 (10.5) 245 (78.3) 10 (3.2) 1 (0.3) 15 (4.8) 9 (2.9)
Health facilities Alamata hospital 248 (10.1) 1929 (78.8) 60 (2.4) 5 (0.2) 44 (1.8) 164 (6.7)
Alamata HC 139 (15.4) 725 (80.5) 13 (1.4) 1 (.1) 4 (0.5) 19 (2.1)
Garjale HC 24 (7.6) 257 (81.9) 13 (4.1) 0 (.0) 13 (4.1) 7 (2.3)
Timuga HC 59 (12.4) 351 (73.7) 31 (6.5) 7 (1.5) 13 (2.7) 15 (3.2)
Selen whua HC 21 (15.7) 100 (74.6) 9 (6.7) 0 (0.0) 2 (1.5) 2 (1.5)
95.9 
88.9 89.5 90.3 86.1 
2 4.4 
8.3 8.2 10.7 
2.1 
6.7 











successful unsuccessful transfer out
Fig. 2 Treatment outcomes (expressed in percent) among health 
facilities. This shows variations in treatment outcomes across health 
facilities in the study district
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USA [21, 22] and China (12.2 %) [17], but lower than the 
results of previous studies in Ethiopia (26 %) [23], Zam-
bia (22 %) [24], India (33 %) [25], Europe (31 %) [26] and 
Norway (17  %) [27]. On the other hand, higher level of 
non-adherence was observed in the current study com-
pared to the non-adherence level (4.5  %) reported from 
Kenya [28].
In the current study, the main reasons for non-adher-
ence were forgetting to take medication, being away from 
home, being unable to go to a health facility and nega-
tive drug side effects, which is consistent with the find-
ings of previous Ethiopian studies [10–12]. In the present 
study, the proportion of non-adherence was high among 
frequent alcohol users and smokers, which supports 
Table 4 Associations of selected background characteristics and the likelihood of having unsuccessful TB treatment out-
comes (n = 4275)
SPPTB smear positive pulmonary TB, SNPTB smear negative pulmonary TB, EPTB extra pulmonary TB
Characteristics Unsuccessful treatment  
outcomes
Crude odds  
ratio (95 % CI)




 2007 28 (4.4) 614 (95.6) 0.5 (0.3, 0.9) 0.490 0.8 (0.3, 1.7)
 2008 44 (5.2) 796 (94.8) 0.6 (0.4, 1.0) 0.730 0.9 (0.5, 1.7)
 2009 36 (4.0) 856 (96.0) 0.5 (0.3, 0.8) 0.020 0.5 (0.3, .9)
 2010 34 (4.3) 764 (95.7) 0.5 (0.3, 0.8) 0.010 0.5 (0.3, 0.8)
 2011 47 (5.9) 743 (94.1) 0.7 (0.4, 1.2) 0.090 0.6 (0.4, 1.1)
 2012 26 (8.3) 287 (91.7) Reference Reference
Health facilities
 Alamata hospital 109 (4.4) 2341 (95.6) Reference Reference
 Alamata HC 18 (2.0) 883 (98.0) 0.4 (0.3, 0.7) 0.001 0.4 (0.3, 0.7)
 Garjale HC 26 (8.3) 288 (91.7) 1.9 (1.2, 3.0) <0.001 2.3 (1.5, 3.7)
 Timuga HC 51 (10.7) 425 (89.3) 2.6 (1.8, 3.7) <0.001 2.5 (1.8, 3.6)
 Selen wuha HC 11 (8.2) 123 (91.8) 1.9 (1.0, 3.7) 0.090 1.8 (0.9, 3.5)
Site of illness
 SPPTB 59 (10.0) 530 (90.0) 3.4 (2.4, 4.8) <0.001 3.1 (2.1, 4.5)
 SNPTB 78 (6.2) 1171 (93.8) 2.0 (1.5, 2.8) <0.001 2.1 (1.5, 2.9)
 EPTB 78 (3.2) 2359 (96.8) Reference Reference
HIV
 Positive 52 (8.9) 535 (91.1) 2.1 (1.5, 3.0) 0.004 1.7 (1.2, 2.5)
 Negative 101 (4.4) 2171 (95.6) Reference Reference
 Unknown 62 (4.4) 1354 (95.6) 1.0 (0.7, 1.4) 0.660 0.9 (0.5, 1.6)
Treatment history
 New cases 195 (4.7) 3970 (95.3) Reference
 Retreatment cases 20 (18,2) 90 (81.8) 4.5 (2.7, 7.5) <0.001 2.6 (1.5, 3.7)
Sex
 Male 127 (5.0) 2395 (95.0) 1.0 (0.8, 1.3) 0.980
 Female 88 (5.0) 1665 (95.0) Reference
Age group
 0–14 24 (4.2) 541 (95.8) 0.8 (0.5, 1.3) 0.310
 15–24 39 (3.8) 985 (96.2) 0.7 (0.5, 1.1) 0.090
 25–34 55 (5.4) 958 (94.6) 1.0 (0.7, 1.5) 0.990
 35–44 44 (6.3) 653 (93.7) 1.2 (0.8, 1.8) 0.450
 45+ 53 (5.4) 923 (94.6) Reference
Residence
 Urban 102 (5.0) 1951 (95.0) 1.0 (0.7, 1.3) 0.860
 Rural 113 (5.1) 2109 (94.9) Reference
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the findings of a previous study [29]. These problems of 
non-adherence due to alcohol and smoking would be 
reduced by good communication between patients and 
health providers as well as by counseling. Previous evi-
dence shows that good counseling [30] and good com-
munication between the patient and health professionals 
[31] have a positive effect on patients’ adherence to their 
medication regimen.
Non-adherence to anti-TB treatment can adversely 
affect treatment success rate. Studies show that poor 
adherence to anti-TB treatment leads to treatment fail-
ure and death, while strict adherence helps to achieve the 
desired treatment success rate [32, 33]. In addition to the 
TB treatment adherence study, we assessed TB treatment 
outcomes in the present study area. The results showed 
that 90 % of patients had successful treatment outcomes, 
which is similar to the WHO target of 90 % (updated tar-
get 2011–2015) [34], though the treatment success rates 
varied from 86.1 to 95.9 % across the health facilities. The 
findings of the current study are comparable to the find-
ings of another recent study in Ethiopia [14]. However, 
the proportion of successful treatment outcomes in the 
current study is relatively higher than findings reported 
from central Ethiopia [35], western Ethiopia [36], north-
western Ethiopia [37] and from other African countries 
including Tanzania [38], Nigeria [39] and Sudan [40].
The findings of the present study showed that among 
patients with unsuccessful treatment outcomes, the 
majority (58.6 %) had died. This may be associated with 
HIV, which has been recognized as the most important 
risk factor for unsuccessful TB treatment outcomes. The 
HIV epidemic has a multifaceted negative impact in the 
control of TB [41]. The findings of the present study also 
showed that HIV sero-positive patients were more likely 
to had unsuccessful treatment outcomes (52 out of 587, 
8.9 %) compared to HIV sero- negative patients (101 out 
of 2272, 4.4 %).
This study showed that the overall default rate within 
the target study period was 1.8 %, which is much lower 
than the findings of previous studies in Ethiopia [9, 10, 
42]. It is also lower than the WHO recommended default 
rate of 3 % [43]. This indicates that the present study area 
is on track for the achievement of the Millennium Devel-
opment Goal focusing on the control of TB. It was also 
noted that patients on re-treatment (4.5  %) were more 
likely to default than new cases (1.7 %). This finding is in 
line with the findings of previous studies in Ethiopia [13, 
14] and a study conducted in Morocco [3].
The treatment success of 83 % among SPPTB cases, in 
the current study is slightly low than the WHO targeted 
treatment success of 90  % for SPPTB cases. However, 
unsuccessful treatment outcomes were similar among 
urban and rural residents, which is inconsistent with 
the results of a previous retrospective study conducted 
in the Southern Region of Ethiopia, which reported 
that patients residing in urban areas had higher rates of 
unsuccessful treatment outcomes compared to patients 
from rural areas [13]. This difference may be due a dif-
ference in interventions and the duration of the study 
period.
Strength and limitations of the study
In the anti-TB treatment adherence component of the 
current study, we attempted to ascertain the level of 
TB treatment adherence in all forms of TB patients 
who received their treatment at several health facilities 
in the study area and this could be considred as one of 
the strengths of the study. However, treatment adher-
ence was assessed based on data from the past 1 month 
and patients’ self-report. Treatment adherence among 
younger patients (i.e. below 15  years of age) and those 
TB patients who followed their treatment at the health 
post level was not evaluated, which could be considered 
as the main limitations of the study. Similarly, treat-
ment outcomes were assessed in all forms of TB patients 
who were treated at the different health facilities within 
5  years and 6  months period. Nevertheless, it was not 
possible to determine all factors which could affect treat-
ment outcomes since the results were based on second-
ary data which routinely collected from health facilities. 
Moreover, since the study did not include health posts it 
is difficult to generalize the findings of this study to all TB 
patients who are treated at health posts and other health 
facilities in the study area.
In conclusion, the level of adherence (88.5 %) observed 
in the current study area is relatively high. The treatment 
success rate (90 %) observed in the present study is also 
high. These are good practices in the study area, because 
effective treatment is not only an essential component 
of good patient care, but also a key element of the pub-
lic health response to TB. However, still further effort like 
health education to patient or family is needed to reduce 
those factors which affect adherence and treatment suc-
cess rates in order to ensure higher rates of adherence 
and treatment success in the present study area.
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